sanrosa (COL-118) phase 2 looking promising

As was mentioned in January this year, COL-118 (product code used for the sansrosa product) is expected to move from Phase 1 to Phase 2 in 2007. Collagenex has published results from their Phase 2 trials that were conducted in order to test some dosage levels to assess how they effective they are and also any side effects.

Some interesting points in their press release: CollaGenex Pharmaceuticals Announces Highly Positive Results of Phase 2 Dose-Finding Trial of Col-118 for the Treatment of Erythema

• 3 dosages were compared to a vehicle control
• The dosage trials measured facial redness on a scale of 0 to 4, with 4 reserved for `fiery redness’. All trial participants were initially assessed as either a 3 or 4 on this scale.
• The best news from the trial was that there was a good relationship between the dosage used, and the benefit measured. This is good news because it shows that the active ingredient can be proven to be effective.
• The trial participants reported at least 6 hours of relief.
• Over a third of the trialists using the highest dosage reported that their redness was rated as a 0 or 1 during the period that the topical was working at its best.
• the side effects of the active formulation was similar to that of the vehicle control ie. no extra bad effects were seen.
• Phase 3 testing is expected in the first quarter of 2008

Overall this is great news for those following the Sansrosa product. The product still needs further trials to confirm its safety and efficacy, and then will require approval by the FDA before it can become generally available.

Related Articles:

• sansrosa patent
• sansrosa started as eye drops ?
• collagenex: rosacea is a chronic inflammatory disease

Read more about: sansrosa